Business Context and Reporting Period
Company: Intelligent Bio Solutions Inc. (INBS)
Filing Type: Form 8-K (Current Report)
Date of Report: August 31, 2026
Event Date: August 31, 2026 (Agreement); September 2, 2026 (Closing)
Context: The Company entered into a Securities Purchase Agreement with a single institutional investor for a private placement offering of equity securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $5.0 million (before fees and expenses).
- Securities Issued:
- 2,036,659 Pre-Funded Warrants (issued in lieu of Common Stock).
- Series N-1 Warrants to purchase up to 2,036,659 shares.
- Series N-2 Warrants to purchase up to 2,036,659 shares.
- Purchase Price: $2.455 per unit (one Pre-Funded Warrant + one Series N-1 Warrant + one Series N-2 Warrant).
- Warrant Exercise Prices:
- Pre-Funded Warrants: $0.01 per share.
- Series N-1 and N-2 Warrants: $2.33 per share.
- Placement Agent Fees:
- Cash fee: 8.0% of gross proceeds.
- Management fee: 1.0% of gross proceeds.
- Future cash fee: 9.0% of proceeds from cash exercise of warrants.
- Warrants: 5.0% of aggregate shares sold (101,833 shares) at $3.06875 exercise price.
- Expense reimbursement: Up to $145,000.
- Use of Proceeds: Working capital and general corporate purposes.
Material Changes and Conditions
This filing reports a material definitive agreement and unregistered sales of equity securities. The transaction resulted in immediate dilution through the issuance of Pre-Funded Warrants and potential future dilution via warrants.
- Series N-1 Callability: Callable by the Company upon public announcement of receiving 510(k) clearance from the FDA for the Intelligent Fingerprinting Drug Screening System.
- Series N-2 Exercisability: Exercisable only after obtaining shareholder approval for the issuance of underlying shares.
- Registration Rights: The Company agreed to file a resale registration statement by September 15, 2026, and seek effectiveness by October 15, 2026.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize net proceeds for working capital and general corporate purposes. The transaction was executed via a private placement to an accredited investor.
Risks and Contingencies:
- Regulatory Approval: The callability of Series N-1 warrants is contingent on FDA 510(k) clearance, which has not yet been received as of the filing date.
- Shareholder Approval: Series N-2 warrants cannot be exercised until shareholder approval is obtained.
- Dilution: Significant potential dilution exists from the Pre-Funded Warrants and the two series of warrants issued.
- Legal Disclaimer: Representations in the Purchase Agreement are for risk allocation between parties and do not constitute statements of fact for investors.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 9% total cash fees and up to $145,000 in expense reimbursements.
- Confirm the status of the FDA 510(k) clearance application for the Intelligent Fingerprinting Drug Screening System.
- Monitor the filing and effectiveness date of the Resale Registration Statement (targeted for October 15, 2026).
- Review the Company's capitalization table to assess the immediate impact of the 2,036,659 Pre-Funded Warrants on outstanding share count.
- Check for any subsequent filings regarding shareholder approval for the Series N-2 Warrants.